Gilead will pay $3.15 billion upfront and could add another $1.85 billion if certain milestones are met. This gives them access to promising drugs like TUB-040 (for ovarian and lung cancers) and TUB-030 (for multiple solid tumors).
Once the deal wraps up in the second quarter of 2026, Tubulis will become Gilead's dedicated research unit for these advanced cancer therapies.
Despite a small dip in Gilead's stock price after the news, this fits into its bigger plan to stay strong in oncology by snapping up innovative companies.